What's happening
This bill establishes designated sickle cell treatment centers across New York and expands opioid prescription exceptions to include sickle cell disease.
Why it matters
Creates specialized centers for sickle cell care. By establishing five centers of excellence and ten outpatient treatment centers, the bill aims to improve access to specialized, high-quality care for individuals with sickle cell disease, which can help address disparities in treatment outcomes and provide more consistent management of this chronic, complex condition.
Promotes research and medical collaboration. The centers of excellence will be required to affiliate with major research universities and medical colleges, potentially accelerating advancements in sickle cell disease research, fostering innovation in treatment, and facilitating training for healthcare professionals.
Directs new funding to targeted care. The bill allocates dedicated annual funding ($200,000 for each center of excellence and $100,000 for each outpatient center) to support research, management, and equipment, which could enhance the quality of care and ensure that these centers are adequately resourced to meet patient needs.
Eases access to pain management for sickle cell patients. By expanding opioid prescription exceptions to include sickle cell disease (not just cancer and palliative care), the bill recognizes the severe, chronic pain often experienced by these patients and seeks to reduce barriers to appropriate pain relief, addressing a significant source of patient suffering and potential healthcare inequity.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Expand Sickle Cell Treatment Centers
Plain English, a few words. Used as the page title.
Sponsors
History
- Referred to ways and means
- Delivered to assembly
- Passed senateVote 60–0
- Ordered to third reading cal.1629
- Committee discharged and committed to rules
- Print number 1890a
- Amend (t) and recommit to finance
- Reported and committed to finance
- Referred to health
- Returned to senate
- Died in assembly
- Referred to health
Show 6 earlier actions
- Delivered to assembly
- Passed senateVote 62–0
- Advanced to third reading
- 2nd report cal.
- 1st report cal.380
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Expand Sickle Cell Treatment Centers
In Assembly Committee · Ways And Means · Sponsor Alicia Hyndman
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
1890--A
2023-2024 Regular Sessions
IN SENATE
January 17, 2023
Introduced by Sens. SANDERS, ASHBY, CLEARE, COMRIE, GIANARIS, JACKSON, KENNEDY, KRUEGER, MAY, MAYER, MYRIE, PARKER, RAMOS, ROLISON, SEPULVE- DA, SKOUFIS, WEBB -- read twice and ordered printed, and when printed to be committed to the Committee on Health -- recommitted to the Committee on Health in accordance with Senate Rule 6, sec. 8 -reported favorably from said committee and committed to the Committee on Finance -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee
AN ACT to amend the public health law, in relation to establishing the "Syd O. Sotillo Sickle Cell Treatment Act"
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Short title. This act shall be known and may be cited as the "Syd O. Sotillo Sickle Cell Treatment Act".
§ 2. The public health law is amended by adding a new section 2807-bb to read as follows:
§ 2807-bb. Sickle cell centers for excellence and outpatient treatment centers. 1. Centers for sickle cell care excellence. The commissioner shall designate five general hospitals or hospices under article forty of this chapter, upon successful application, as centers for sickle cell care excellence. The designations shall be made through an application designed by the department, and based on service, staffing and other criteria as developed by the commissioner. The centers of excellence shall provide specialized sickle cell disease care, treatment, palliative care, education and related services and shall conduct specialized research into the care, treatment and management of sickle cell disease. Designation as a center for sickle cell care excellence shall not entitle a center to enhanced reimbursement, but may be utilized in outreach and other promotional activities. Each center for sickle cell care excellence shall affiliate and cooperate with major centers of higher learning, including medical colleges, and life science research insti-
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD05963-02-4
tutes in the state. The state university shall enter into appropriate legal agreements to enable this cooperation. Each center for sickle cell care excellence shall receive two hundred thousand dollars per year from the department, from amounts appropriated for that purpose, to be used on sickle cell disease research.
2. Outpatient treatment centers. The commissioner shall designate ten hospitals, distributed based on sickle cell patient population concentrations, as sickle cell outpatient treatment centers which shall provide patients treatment for sickle cell disease as an outpatient. Each sickle cell outpatient treatment center shall receive one hundred thousand dollars per year from the department, from amounts appropriated for that purpose, to be used to ensure the proper management and equipping of the centers to care for sickle cell patients.
§ 3. Subdivision 8 of section 3331 of the public health law, as added by section 7-a of part D of chapter 57 of the laws of 2018, is amended to read as follows:
8. No opioids shall be prescribed to a patient initiating or being maintained on opioid treatment for pain which has lasted more than three months or past the time of normal tissue healing, unless the medical record contains a written treatment plan that follows generally accepted national professional or governmental guidelines. The requirements of this paragraph shall not apply in the case of patients who are being treated for cancer or sickle cell disease that is not in remission, who are in hospice or other end-of-life care, or whose pain is being treated as part of palliative care practices.
§ 4. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the public health law, in relation to establishing the "Syd O. Sotillo Sickle Cell Treatment Act"
Purpose
Establishes the Sickle Cell Treatment Act
Summary of specific provisions
Section 1 of the bill would set forth that this act shall be known and may be cited as the "Syd O. Sotillo Sickle Cell Treatment Act".
Section 2 amends the public health law by adding a new section 2807-aa which mandates the Commissioner of the Department of Health to designate Sickle cell centers for excellence and outpatient treatment centers.
Section 3 amends subdivision 8 of section 3331 of the public health law, as added by section 7-a of part D of chapter 57 of the laws of 2018 relating to opioid exemption.
Section 4 provides the effective date.
Justification
Sickle Cell patients experience a multitude of symptoms that can range from mild to severe. There is little to no awareness of possible ways to manage these symptoms, which is why centers for excellence (COE), and outpatient treatment centers are essential.
The Centers of Excellence would serve as a hub for adults and children alike to have access to professionals that can understand, monitor, and provide care in the most effective way possible. The COEs would further serve as leaders to other institutions in the treatment of SCD and would establish the best practices that could then be used in other healthcare facilities around the state.
Outpatient hospitals would help reduce the need of sickle cell patients to check into the emergency room for pain, which is the traditional response of people who are suffering an SCD pain crisis. Patients would have access to readily available services that are designated to help specifically with SCD pain management and symptoms because outpatient services would be available in areas where there is sufficient need for the service. The reduced burden on emergency rooms, especially in times of health crisis, can help patients and doctors alike.
Pain is a major symptom of Sickle Cell disease (SCD) and one of the principal reasons that people with SCD go to the emergency room... Pain experienced by sickle cell patients manifests itself as abrupt and very debilitating pain in any part of the body. Individuals diagnosed with sickle cell can begin having pain crises as early as 6 months of age. This legislation will allow certain sickle cell patients to easily gain access to opioid therapy. Currently, sickle cell patients are restricted in being treated with opioids. However, due to the debilitating pain
sickle cell disease patients encounter during crisis, opioid therapy serves to reduce the pain that patients experience.
Syd Sotillo, 30, of Brooklyn, New York passed away on April 20, 2012, as a result of medical issues including sickle cell anemia. This bill is named in memory of him.
Legislative history
2022 REPORTED FROM HEALTH AND COMMITTED TO SENATE FINANCE
2022 referred to assembly ways and means
2021 REFERRED TO SENATE HEALTH
2021 reported from health referred to assembly ways and means
Fiscal implications
To be determined
Effective date
This act shall take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.